Sante Neuro Bioscience Raises 20 Billion KRW in Series A Funding

Used for Clinical Entry of Core Pipeline 'CTN001' and More

[Asia Economy Reporter Lee Gwan-joo] Medytox’s affiliate Santnear Biosciences recently announced on the 23rd that it has secured a total of 20 billion KRW in Series A funding from Bionote, an affiliate of SD Biosensor, and SDV Investment.

Santnear, which is developing an innovative antibody platform focused on cancer and immune disease treatments, succeeded in raising a large-scale investment just 10 months after its establishment. The funds will be used for the development to enter clinical trials of its core pipeline ‘CTN001,’ pipeline expansion, and additional platform technology development.

Santnear’s core pipeline, the next-generation HER2-targeting antibody ‘CTN001,’ targets HER2-low breast cancer rather than HER2-positive breast cancer, which is the target of existing HER2-targeting antibodies. HER2-low breast cancer is a newly classified cancer type that accounts for more than 50% of all breast cancers, but there is currently no approved targeted therapy.

Yang Ki-hyuk, CEO of Santnear, said, “With this Series A investment as a turning point, we will advance and expand the development stage of antibody pipelines applying our platform technology. Leading with our main pipeline CTN001, we will develop safe and effective antibody drugs to prove Santnear’s unique value.”

Santnear is a newly established bio company founded to develop a next-generation antibody platform based on innovative antibody technology introduced from Medytox by CEO Yang, who was a founding member of Medytox and previously led research and development (R&D), along with other researchers.

This content was produced with the assistance of AI translation services.